Cargando…
Public–private partnership alternative for a national pharmacare program in Canada
BACKGROUND: Recently, the government and an opposition party cut a deal that involved a promise to consider implementing a single-payer pharmacare scheme in Canada in exchange for supporting the current minority government. There have been political headwinds from the private extended health insuran...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903457/ https://www.ncbi.nlm.nih.gov/pubmed/36747233 http://dx.doi.org/10.1186/s40545-023-00526-3 |
_version_ | 1784883476338573312 |
---|---|
author | Nauenberg, Eric Yurga, Emre |
author_facet | Nauenberg, Eric Yurga, Emre |
author_sort | Nauenberg, Eric |
collection | PubMed |
description | BACKGROUND: Recently, the government and an opposition party cut a deal that involved a promise to consider implementing a single-payer pharmacare scheme in Canada in exchange for supporting the current minority government. There have been political headwinds from the private extended health insurance industry, the provinces of Ontario and Quebec, as well as the pharmaceutical industry. We suggest a new multiple-payer of mixed-resort framework that achieves both the goal of universal coverage and preserves the private extended health insurance industry through a scheme based on the current coordination of benefits between private payers in this sector. METHODS: We employ game theory to better understand the dynamics within a market that involves multiple payers. In particular, we use the game of Collective Action to help illustrate the problems of free-ridership. RESULTS: An analysis of the dynamics of this market suggests that ex–ante agreements need to be struck between all payers in a multi-payer marketplace to achieve both stability and sustainability of such a framework. CONCLUSION: We show that universal coverage is still possible while leveraging the existing system of private extended health insurance so long as a well-established system for coordinating benefits between public and private payers is established. A stable public/private partnership can achieve universal coverage so long as a system for coordinating benefits is instituted. The proposed alternative will achieve the same goals, but maintain a niche for the private sector thereby maintaining therapeutic variety in the marketplace. |
format | Online Article Text |
id | pubmed-9903457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99034572023-02-08 Public–private partnership alternative for a national pharmacare program in Canada Nauenberg, Eric Yurga, Emre J Pharm Policy Pract Policy Analysis BACKGROUND: Recently, the government and an opposition party cut a deal that involved a promise to consider implementing a single-payer pharmacare scheme in Canada in exchange for supporting the current minority government. There have been political headwinds from the private extended health insurance industry, the provinces of Ontario and Quebec, as well as the pharmaceutical industry. We suggest a new multiple-payer of mixed-resort framework that achieves both the goal of universal coverage and preserves the private extended health insurance industry through a scheme based on the current coordination of benefits between private payers in this sector. METHODS: We employ game theory to better understand the dynamics within a market that involves multiple payers. In particular, we use the game of Collective Action to help illustrate the problems of free-ridership. RESULTS: An analysis of the dynamics of this market suggests that ex–ante agreements need to be struck between all payers in a multi-payer marketplace to achieve both stability and sustainability of such a framework. CONCLUSION: We show that universal coverage is still possible while leveraging the existing system of private extended health insurance so long as a well-established system for coordinating benefits between public and private payers is established. A stable public/private partnership can achieve universal coverage so long as a system for coordinating benefits is instituted. The proposed alternative will achieve the same goals, but maintain a niche for the private sector thereby maintaining therapeutic variety in the marketplace. BioMed Central 2023-02-06 /pmc/articles/PMC9903457/ /pubmed/36747233 http://dx.doi.org/10.1186/s40545-023-00526-3 Text en © Crown 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Policy Analysis Nauenberg, Eric Yurga, Emre Public–private partnership alternative for a national pharmacare program in Canada |
title | Public–private partnership alternative for a national pharmacare program in Canada |
title_full | Public–private partnership alternative for a national pharmacare program in Canada |
title_fullStr | Public–private partnership alternative for a national pharmacare program in Canada |
title_full_unstemmed | Public–private partnership alternative for a national pharmacare program in Canada |
title_short | Public–private partnership alternative for a national pharmacare program in Canada |
title_sort | public–private partnership alternative for a national pharmacare program in canada |
topic | Policy Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903457/ https://www.ncbi.nlm.nih.gov/pubmed/36747233 http://dx.doi.org/10.1186/s40545-023-00526-3 |
work_keys_str_mv | AT nauenbergeric publicprivatepartnershipalternativeforanationalpharmacareprogramincanada AT yurgaemre publicprivatepartnershipalternativeforanationalpharmacareprogramincanada |